Compare ZNB & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZNB | GRI |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | 2018 | 2020 |
| Metric | ZNB | GRI |
|---|---|---|
| Price | $0.43 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | ★ 2.6M | 38.8K |
| Earning Date | 10-19-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.18 |
| 52 Week High | $9.78 | $64.12 |
| Indicator | ZNB | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 34.98 |
| Support Level | $0.22 | N/A |
| Resistance Level | $1.93 | $2.66 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 6.67 | 2.16 |
Zeta Network Group consist principally of cryptocurrency mining. The company conducts business as two operating segments which comprise of consulting services and cryptocurrency mining. Majority of revenue comes from cryptocurrency mining segment.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.